Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 6/20 | 0.59 |
| ▸ | MDM4 | O15151 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | TLR2 | O60603 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29379713 | 1.00 | MDM2 (0.59) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL29470876 | 1.00 | MDM2 (0.59) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL19402725 | 1.00 | MDM2 (0.59) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL13402819 | 1.00 | MDM2 (0.59) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL29400571 | 0.93 | MDM2 (0.53) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL12527832 | 0.93 | MDM2 (0.53) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL31614333 | 0.93 | MDM2 (0.53) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL6158363 | 0.91 | MDM2 (0.57) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL436024 | 0.91 | MDM2 (0.57) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL31681399 | 0.91 | MDM2 (0.57) | MDM2MDM4TP53TLR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117986349-B | Semex lattice preparation method of lupeptide | 福建基诺厚普生物科技有限公司 | 2024-10-01 | — | — | CN | claimed |
| CN-117986349-A | Preparation method of semaglutin | 福建基诺厚普生物科技有限公司 | 2024-05-07 | — | — | CN | claimed |
| CN-117801052-A | Method for synthesizing Fmoc-Lys (MMT) -OH | 常州吉恩药业有限公司 | 2024-04-02 | — | — | CN | claimed |
| CN-115894633-A | Preparation method of RGD cyclopeptide precursor | 滨海吉尔多肽有限公司 | 2023-04-04 | — | — | CN | claimed |
| US-20250332184-A1 | NEOADJUVANT USE OF ANTIBODY-DRUG CONJUGATES | IMMUNOMEDICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| CN-120192374-A | Targeted SctV cyclic peptide for inhibiting T3SS activity and application thereof | 山东大学 | 2025-06-24 | — | — | CN | disclosed |
| EP-4569330-A1 | NOVEL PORE MONOMERS AND PORES | Oxford Nanopore Technologies PLC (GB) | 2025-06-18 | — | — | EP | disclosed |
| CN-119654167-A | Nucleic acid compositions comprising amphiphilic oligoethylene glycol (OEG) conjugated compounds and methods of using such compounds and compositions | 生物技术公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-119630970-A | Novel Kong Shanti and holes | 牛津纳米孔科技公开有限公司 | 2025-03-14 | — | — | CN | disclosed |
| WO-2025027389-A1 | BIOLOGICALLY ACTIVE COMPOUNDS COMPRISING A STAPLED OR STITCHED PEPTIDE | SUTURA THERAPEUTICS LIMITED (GB) | 2025-02-06 | — | — | WO | disclosed |
| WO-2025027181-A1 | AGENTS AND METHODS FOR TARGETED DELIVERY TO CELLS | BioNTech SE (DE) | 2025-02-06 | — | — | WO | disclosed |
| EP-4472998-A1 | CYCLIC EPITOPE TAGS | BioNTech SE (DE) | 2024-12-11 | — | — | EP | disclosed |
| WO-2023023889-A1 | METHOD OF SYNTHESIZING DENDRIMERIC AMPHIPHILE | KAOHSIUNG MEDICAL UNIVERSITY (CN) | 2023-03-02 | — | — | WO | disclosed |
| CN-115052632-A | Targeted polypeptide-drug conjugates and uses thereof | 北京海步医药科技有限公司 | 2022-09-13 | — | — | CN | disclosed |
| CN-115003679-A | Conjugates of phthalocyanine dyes and antibodies or peptides | 国立大学法人东京大学 | 2022-09-02 | — | — | CN | disclosed |
| CN-109562172-B | Efficacy of anti-HLA-DR antibody drug conjugate IMMU-140(hL243-CL2A-SN-38) in HLA-DR positive cancers | 免疫医疗公司 | 2022-08-16 | — | — | CN | disclosed |
| CN-110003055-B | Amino diacids containing peptide modifiers | 佩特雷化学和生物制药学实验室有限公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-108853514-B | Antibody drug conjugates with two different drugs | 四川百利药业有限责任公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-113444164-B | Solid-phase synthesis method of Somalutide | 台州吉诺生物科技有限公司 | 2022-07-19 | — | — | CN | disclosed |
| CN-110294800-B | Preparation method of somaglutide | 齐鲁制药有限公司 | 2022-03-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332184-A1 | NEOADJUVANT USE OF ANTIBODY-DRUG CONJUGATES | ENTPD1, ENTPD2, ENTPD8 | MDM2 1487/4885MDM4 1090/4885TP53 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.